Search results for "Secondary"

showing 10 items of 1765 documents

Epizootic of dolphin morbillivirus on the Catalonian Mediterranean coast in 2007

2011

BETWEEN 1990 and 1992, thousands of striped dolphins (Stenella coeruleoalba) stranded along the Mediterranean coast due to a newly described virus, the dolphin morbillivirus (DMV) (Domingo and others 1990, 1992). DMV is one of the several morbilliviruses that have killed marine mammals worldwide since 1987 (Di Guardo and others 2005). A new DMV epizootic has been recently confirmed from the Mediterranean Spanish and French coasts during 2007 to 2008 (Fernández and others 2008, Raga and others 2008, Keck and others 2010). This short communication describes the pathological findings associated with DMV infection and secondary infections, observed during this epizootic on the Mediterranean coa…

MaleMediterranean climateDIAGNOSIS (VETERINARY MEDICINE)Secondary infectionPATOLOGÍA ANIMALZoologyStenella coeruleoalbaNeutral buffered formalinBiologyDisease OutbreaksStenellaMorbillivirusDELPHINbiology.animalDIAGNOSTICO (MEDICINA VETERINARIA)medicineAnimalsGrampus griseusEpizooticGeneral VeterinaryCanine distemperANIMAL PATHOLOGYGeneral Medicinebiology.organism_classificationmedicine.diseaseImmunohistochemistryFisherySpainFemaleDELFINhuman activitiesMorbillivirus Infections
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

Not Only for Egg Yolk—Functional and Evolutionary Insights from Expression, Selection, and Structural Analyses of Formica Ant Vitellogenins

2014

Vitellogenin (Vg), a storage protein, has been extensively studied for its egg-yolk precursor role, and it has been suggested to be fundamentally involved in caste differences in social insects. More than one Vg copy has been reported in several oviparous species, including ants. However, the number and function of different Vgs, their phylogenetic relatedness, and their role in reproductive queens and nonreproductive workers have been studied in few species only. We studied caste-biased expression of Vgs in seven Formica ant species. Only one copy of conventional Vg was identified in Formica species, and three Vg homologs, derived from ancient duplications, which represent yet undiscovered…

MaleModels Molecularfood.ingredientProtein ConformationSequence HomologyHymenopteraProtein Structure SecondaryEvolution MolecularVitellogeninsVitellogeninfoodPhylogeneticsGene DuplicationYolkGene duplicationGeneticsAnimalsSelection GeneticMolecular BiologyGenePhylogenyEcology Evolution Behavior and SystematicsGeneticsbiologyAntsta1184biology.organism_classificationEvolutionary biologybiology.proteinta1181Insect ProteinsFemaleNeofunctionalizationVitellogeninsMolecular Biology and Evolution
researchProduct

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, second…

2002

Abstract Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response…

MaleMyeloidmedicine.drug_classmedicine.medical_treatmentImmunologyAntineoplastic AgentsBiochemistryTyrosine-kinase inhibitorPiperazinesBone MarrowRecurrencehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineSecondary Acute Myeloid LeukemiaHumansReceptors Platelet-Derived Growth FactorEnzyme InhibitorsneoplasmsSalvage TherapyChemotherapyAnemia Refractory with Excess of Blastsbusiness.industryAnemia RefractoryDaunorubicinRemission InductionCytarabineMyeloid leukemiaCell BiologyHematologyExonsMiddle Agedmedicine.diseaseNeoplasm ProteinsLeukemiaLeukemia Myeloid AcuteProto-Oncogene Proteins c-kitmedicine.anatomical_structureImatinib mesylatePyrimidinesDrug Resistance NeoplasmImmunologyBenzamidesCancer researchDisease ProgressionImatinib MesylateNeoplastic Stem CellsBone marrowbusinessBlood
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOL…

2020

PurposeThe objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders.MethodsThis study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed. In 230 patients, computed texture analysis was performed on the dominant liver lesion (DLL) at baseline and 2 months after chemotherapy. RECIST1·1 evaluation was performed at 6 months. …

MaleOncologyColorectal cancermedicine.medical_treatmentLeucovorinKaplan-Meier Estimate030218 nuclear medicine & medical imagingMESH: Camptothecin / administration & dosage; Camptothecin / analogs & derivatives; Colorectal Neoplasms / drug therapy; Colorectal Neoplasms / pathology; Computational Biology; Female0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overLiver NeoplasmsGastroenterologyMESH: Radiographic Image Interpretation Computer-Assisted; Response Evaluation Criteria in Solid Tumors; Survival Rate;Tomography X-Ray ComputedMiddle AgedBevacizumabSurvival Rate030220 oncology & carcinogenesisCohortFOLFIRIRadiographic Image Interpretation Computer-AssistedFemaleFluorouracilColorectal NeoplasmsClinical decision makingmedicine.drugAdultmedicine.medical_specialtyBevacizumab[SDV.CAN]Life Sciences [q-bio]/CancerMESH: Fluorouracil / administration & dosage; Humans; Kaplan-Meier Estimate; Leucovorin / administration & dosage; Liver Neoplasms / diagnostic imagingComputerised image analysis03 medical and health sciencesColorectal metastasesMESH: Adult; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols / administration & dosage; Bevacizumab / administration & dosage; Camptothecin / administration & dosagePredictive Value of TestsInternal medicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansChemotherapyResponse Evaluation Criteria in Solid TumorsMESH: Liver Neoplasms / secondary; Male; Middle Aged; Predictive Value of Tests; Prospective StudiesAgedChemotherapybusiness.industryComputational Biology[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseColorectal cancerLog-rank testIrinotecanCamptothecinTomography X-Ray ComputedbusinessGut
researchProduct

A new mitochondrial point mutation in the transfer RNALys gene associated with progressive external ophthalmoplegia with impaired respiratory regulat…

2011

Abstract We report a novel heteroplasmic point mutation G8299A in the gene for mitochondrial tRNA Lys in a patient with progressive external ophthalmoplegia complicated by recurrent respiratory insufficiency. Biochemical analysis of respiratory chain complexes in muscle homogenate showed a combined complex I and IV deficiency. The transition does not represent a known neutral polymorphism and affects a position in the tRNA acceptor stem which is conserved in primates, leading to a destabilization of this functionally important domain. In vitro analysis of an essential maturation step of the tRNA transcript indicates the probable pathogenicity of this mutation. We hypothesize that there is a…

MaleOphthalmoplegia Chronic Progressive ExternalRNA MitochondrialMitochondrial diseaseMolecular Sequence DataRespiratory chainBiologymedicine.disease_causeSecondary PreventionmedicineHumansPoint MutationGeneticsMutationBase SequenceTransition (genetics)Point mutationExternal ophthalmoplegiaMiddle Agedmedicine.diseaseHeteroplasmyNeurologyRespiratory failureRNARNA Transfer LysNeurology (clinical)Respiratory InsufficiencyJournal of the Neurological Sciences
researchProduct

Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insuf…

2020

BACKGROUND: Autoimmune pancreatitis (AIP) is a rare, and relatively new, form of chronic pancreatitis. The management of AIP can vary considerably among different centres in daily clinical practice. OBJECTIVES: The aim of this study is to present a picture of epidemiological, clinical characteristics, outcomes, and the real-life practice in terms of management in several academic and non-academic centres in Italy. METHODS: Data on the clinical presentation, diagnostic work-up, treatments, frequency of relapses, and long-term outcomes were retrospectively collected in a cohort of AIP patients diagnosed at 14 centres in Italy. RESULTS: One hundred and six patients were classified as type 1 AI…

MalePediatricsBiopsyAftercareAzathioprineFeces0302 clinical medicineRecurrencePrednisoneSecondary PreventionPractice Patterns Physicians'Autoimmune pancreatitisEndoscopic retrograde cholangiopancreatographyPancreatic Elastasemedicine.diagnostic_testGastroenterologyfood and beveragesMiddle AgedJaundiceItalyOncology030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyRituximabGuideline Adherencesteroid trialmedicine.symptomRituximabImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyfine needle aspiration/biopsyNausea03 medical and health sciencesmedicineHumansGlucocorticoidsPancreasRetrospective StudiesAutoimmune pancreatitisbusiness.industryEndoscopyOriginal Articlespancreatic insufficiencymedicine.diseaseendoscopic ultrasoundPancreatitisbusinessFollow-Up StudiesUnited European Gastroenterology Journal
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-…

2003

To evaluate immune responses, safety and reactogenicity of the concomitant use of DTaP-IPV-Hib and the newly available 7-valent pneumococcal conjugate (7VPnC) vaccines when given as the primary immunization series in early infancy. A total of 231 healthy infants were enrolled at 11 German study centers and randomized to receive either 7VPnC plus DTaP-IPV-Hib vaccines concomitantly into opposite limbs at age 2, 3, 4 and 11-15 months (7VPnC group) or DTaP-IPV-Hib vaccine at the same ages plus a 7VPnC "catch-up vaccination" at ages 6, 7, 8 and 11-15 months (Control group). Blood samples were drawn before and 4 weeks after the first three vaccine doses and 4 weeks after the fourth dose. Local a…

MalePediatricsmedicine.medical_specialtyImmunization SecondaryEnzyme-Linked Immunosorbent AssayHerpesvirus VaccinesAntibodies ViralPneumococcal conjugate vaccinePneumococcal VaccinesmedicineHumansVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHerpesvirus 1 BovineReactogenicityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryDiphtheriaImmunogenicityPublic Health Environmental and Occupational HealthInfantmedicine.diseaseAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesImmunizationConcomitantChild PreschoolImmunologyMolecular MedicineFemalePertactinbusinessmedicine.drugVaccine
researchProduct